Switch theme
Sign up to access all valuation multiples
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
2002
3.1K+
LTM Revenue $1.2B
LTM EBITDA $492M
$9.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
HealthEquity has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $492M.
In the most recent fiscal year, HealthEquity achieved revenue of $1.2B and an EBITDA of $339M.
HealthEquity expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HealthEquity valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Profit | $810M | XXX | $777M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $492M | XXX | $339M | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $194M | XXX | $203M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $120M | XXX | $96.7M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $760M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, HealthEquity's stock price is $101.
HealthEquity has current market cap of $8.7B, and EV of $9.5B.
See HealthEquity trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.5B | $8.7B | XXX | XXX | XXX | XXX | $3.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, HealthEquity has market cap of $8.7B and EV of $9.5B.
HealthEquity's trades at 8.1x EV/Revenue multiple, and 28.5x EV/EBITDA.
Equity research analysts estimate HealthEquity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HealthEquity has a P/E ratio of 72.9x.
See valuation multiples for HealthEquity and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.7B | XXX | $8.7B | XXX | XXX | XXX |
| EV (current) | $9.5B | XXX | $9.5B | XXX | XXX | XXX |
| EV/Revenue | 7.7x | XXX | 8.1x | XXX | XXX | XXX |
| EV/EBITDA | 19.4x | XXX | 28.5x | XXX | XXX | XXX |
| EV/EBIT | 49.0x | XXX | 48.5x | XXX | XXX | XXX |
| EV/Gross Profit | 11.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 72.9x | XXX | 93.4x | XXX | XXX | XXX |
| EV/FCF | 28.7x | XXX | -70.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHealthEquity's last 12 month revenue growth is 9%
HealthEquity's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
HealthEquity's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HealthEquity's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for HealthEquity and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 36% | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Star Health Insurance | XXX | XXX | XXX | XXX | XXX | XXX |
| Hapvida | XXX | XXX | XXX | XXX | XXX | XXX |
| Qualicorp | XXX | XXX | XXX | XXX | XXX | XXX |
| Accolade | XXX | XXX | XXX | XXX | XXX | XXX |
| AIX Inc. | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HealthEquity acquired XXX companies to date.
Last acquisition by HealthEquity was XXXXXXXX, XXXXX XXXXX XXXXXX . HealthEquity acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was HealthEquity founded? | HealthEquity was founded in 2002. |
| Where is HealthEquity headquartered? | HealthEquity is headquartered in United States of America. |
| How many employees does HealthEquity have? | As of today, HealthEquity has 3.1K+ employees. |
| Who is the CEO of HealthEquity? | HealthEquity's CEO is Mr. Scott R. Cutler. |
| Is HealthEquity publicy listed? | Yes, HealthEquity is a public company listed on NAS. |
| What is the stock symbol of HealthEquity? | HealthEquity trades under HQY ticker. |
| When did HealthEquity go public? | HealthEquity went public in 2014. |
| Who are competitors of HealthEquity? | Similar companies to HealthEquity include e.g. Star Health Insurance, Hapvida, Qualicorp, Accolade. |
| What is the current market cap of HealthEquity? | HealthEquity's current market cap is $8.7B |
| What is the current revenue of HealthEquity? | HealthEquity's last 12 months revenue is $1.2B. |
| What is the current revenue growth of HealthEquity? | HealthEquity revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of HealthEquity? | Current revenue multiple of HealthEquity is 7.7x. |
| Is HealthEquity profitable? | Yes, HealthEquity is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of HealthEquity? | HealthEquity's last 12 months EBITDA is $492M. |
| What is HealthEquity's EBITDA margin? | HealthEquity's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of HealthEquity? | Current EBITDA multiple of HealthEquity is 19.4x. |
| What is the current FCF of HealthEquity? | HealthEquity's last 12 months FCF is $332M. |
| What is HealthEquity's FCF margin? | HealthEquity's last 12 months FCF margin is 27%. |
| What is the current EV/FCF multiple of HealthEquity? | Current FCF multiple of HealthEquity is 28.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
